PMID- 9224752
OWN - NLM
STAT- MEDLINE
DCOM- 19970729
LR  - 20190722
IS  - 0046-8177 (Print)
IS  - 0046-8177 (Linking)
VI  - 28
IP  - 7
DP  - 1997 Jul
TI  - HER-2/neu gene amplification status in prostate cancer by fluorescence in situ 
      hybridization.
PG  - 827-33
AB  - HER-2/neu expression has been established as a prognostic factor in breast and 
      other cancers. In prostate cancer (PC), a similar predictive role has been 
      hindered by variable immunohistochemical (IHC) results. The authors studied DNA 
      amplification of the HER-2/neu gene on 4-microm sections obtained from 62 
      formalin-fixed, paraffin-embedded PCs by fluorescence in situ hybridization 
      (FISH). The results were compared with HER-2/neu protein expression as determined 
      by IHC and correlated by logistic regression analysis with Gleason tumor grade, 
      DNA ploidy, serum prostate specific antigen (PSA), and pathological stage. The 
      HER-2/neu gene was localized using the Oncor (Gaithersburg, MD) 
      digoxigenin-labeled unique sequence probe. Amplified PCs had at least 20 
      malignant cells, with 5 or more copies of the sequence. Amplification of 
      HER-2/neu correlated with Gleason score (P = .0001). The mean Gleason score of 
      unamplified tumors was 5.7 and that of amplified tumors was 7.5. Nondiploid 
      tumors had a significantly greater rate of HER-2/neu amplification compared with 
      diploid tumors (P = .0003). Of the 62 cases evaluated by IHC and FISH, 18 cases 
      (29%) were overexpressed by IHC, and 27 cases (44%) were amplified by FISH. A 
      trend for similar HER-2/neu status in each PC by the two methods did not reach 
      statistical significance (P = .23). HER-2/neu amplification by FISH was 
      associated with advanced pathological stage; however, this relationship reached 
      only near-statistical significance (P = .06). There was no correlation of 
      HER-2/neu amplification by FISH with patient age or preoperative serum PSA 
      levels. The authors conclude that HER-2/neu gene amplification status can be 
      determined by FISH on archival prostate cancer specimens, significantly 
      correlates with high tumor grade and nondiploid DNA content, and is more 
      frequently encountered in tumors with advanced pathological stage. Also, FISH is 
      more sensitive than IHC for detection of abnormalities in the HER-2/neu gene, and 
      further studies should be undertaken to determine whether a FISH-based HER-2/neu 
      detection method may prove of importance in the prediction of prognosis and 
      planning of therapy in prostate cancer patients.
FAU - Ross, J S
AU  - Ross JS
AD  - Department of Pathology and Laboratory Medicine, Albany Medical College, NY 
      12208, USA.
FAU - Sheehan, C
AU  - Sheehan C
FAU - Hayner-Buchan, A M
AU  - Hayner-Buchan AM
FAU - Ambros, R A
AU  - Ambros RA
FAU - Kallakury, B V
AU  - Kallakury BV
FAU - Kaufman, R
AU  - Kaufman R
FAU - Fisher, H A
AU  - Fisher HA
FAU - Muraca, P J
AU  - Muraca PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (DNA, Neoplasm)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - DNA, Neoplasm/analysis
MH  - Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Ploidies
MH  - Prognosis
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology
MH  - Receptor, ErbB-2/metabolism
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - S0046-8177(97)90157-X [pii]
AID - 10.1016/s0046-8177(97)90157-x [doi]
PST - ppublish
SO  - Hum Pathol. 1997 Jul;28(7):827-33. doi: 10.1016/s0046-8177(97)90157-x.